Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An announcement from NKGen Biotech ( (NKGN) ) is now available.
NKGen Biotech has announced a delay in filing its quarterly report due to the complex valuation of derivative securities, leading to a notice from Nasdaq for non-compliance with filing rules. Despite this, the company’s stock remains unaffected and it has been granted a temporary exception until January 2025, during which it plans to resolve these issues and potentially acquire a majority interest in NKMax Co. Ltd. Investors should be aware of the potential risks and uncertainties related to these developments.
See more data about NKGN stock on TipRanks’ Stock Analysis page.